Inventor · disambiguated record
Babita Agrawal
Also filed as: AGRAWAL BABITA
10 granted patents·4 pending applications·72 citations·filing 1999–2022
86Inventor score
Top patents by PatentIndex Score
14 records- 0190US6600012B1Lipid-modified muc-1 derivativesBIOMIRA INC·Filed 2000·Granted Jul 29, 2003·43 cites·16 claims
- 0286US10369205B2Immunomodulatory compositions and methods of use thereofAGRAWAL BABITA·Filed 2015·Granted Aug 6, 2019·6 cites·12 claims
- 0382US7589077B2Antiviral nucleosidesKUMAR RAKESH·Filed 2002·Granted Sep 15, 2009·11 cites·9 claims
- 0473US11701393B2Immunomodulatory compositions and methods of use thereofAGRAWAL BABITA·Filed 2022·Granted Jul 18, 2023·0 cites·8 claims
- 0570US11065283B2Immunomodulatory compositions and methods of use thereofAGRAWAL BABITA·Filed 2016·Granted Jul 20, 2021·1 cites·5 claims
- 0669US10946082B2Immunomodulatory compositions and methods of use thereofAGRAWAL BABITA·Filed 2019·Granted Mar 16, 2021·0 cites·10 claims
- 0768US11419904B2Immunomodulatory compositions and methods of use thereofAGRAWAL BABITA·Filed 2021·Granted Aug 23, 2022·0 cites·6 claims
- 0862US8227594B2Antiviral nucleosidesKUMAR RAKESH·Filed 2009·Granted Jul 24, 2012·0 cites·18 claims
- 0962US6602660B1Methods of detecting T-cell activationFiled 2000·Granted Aug 5, 2003·4 cites·6 claims
- 1041US6114129AMethods of detecting T-cell activation and treating disorders associated with T-cell dysfunctionBIOMIRA INC·Filed 1999·Granted Sep 5, 2000·7 cites·5 claims
- 1139US2002142983A1MUC-1 antagonists and methods of treating immune disordersBIOMIRA INC·Filed 2001·Application pending·0 cites
- 1235US2002018806A1Lipopeptide adjuvantsFiled 2001·Application pending·0 cites
- 1334US2018000926A1Methods of inducing an immune response to hepatitis c virusAGRAWAL BABITA·Filed 2016·Application pending·0 cites
- 1430US2002159969A1Small peptide-based therapeutics for reversing cancer-associated MUC-1 mucin-induced immunosuppressionFiled 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →